Browsing by Author "Weiss, Roger D"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Item Open Access Hallucinogen-related disorders in a national sample of adolescents: the influence of ecstasy/MDMA use.(Drug and alcohol dependence, 2009-09) Wu, Li-Tzy; Ringwalt, Christopher L; Weiss, Roger D; Blazer, Dan GTo present the prevalence and correlates of hallucinogen use disorders (HUDs: abuse or dependence) and subthreshold dependence.The study sample included adolescents aged 12-17 years (N=55,286) who participated in the National Survey on Drug Use and Health (2004-2006). Data were collected with a combination of computer-assisted personal interviewing and audio computer-assisted self-interviewing.The overall prevalence of HUDs among adolescents was low (<1%). However, more than one in three (38.5%) MDMA users and nearly one in four (24.1%) users of other hallucinogens reported HUD symptoms. MDMA users were more likely than users of other hallucinogens to meet criteria for hallucinogen dependence: 11% (95% confidence interval [CI]: 8.24-14.81) vs. 3.5% (95% CI: 2.22-5.43). Compared with hallucinogen use only, subthreshold dependence was associated with being female (adjusted odds ratio [AOR]=1.8 [95% CI: 1.08-2.89]), ages 12-13 years (AOR=3.4 [1.64-7.09]), use of hallucinogens > or = 52 days (AOR=2.4 [1.66-6.92]), and alcohol use disorder (AOR=1.8 [1.21-2.77]). Compared with subthreshold dependence, abuse was associated with mental health service use (AOR=1.7 [1.00-3.00]) and opioid use disorder (AOR=4.9 [1.99-12.12]); dependence was associated with MDMA use (AOR=2.2 [1.05-4.77]), mental health service use (AOR=2.9 [1.34-6.06]), and opioid use disorder (AOR=2.6 [1.01-6.90]). MDMA users had a higher prevalence of most other substance use disorders than users of non-hallucinogen drugs.Adolescent MDMA users appear to be particularly at risk for exhibiting hallucinogen dependence and other substance use disorders.Item Open Access The Opioid Use Disorder Core Outcomes Set (OUD-COS) for treatment research: findings from a Delphi consensus study.(Addiction (Abingdon, England), 2022-03-16) Karnik, Niranjan S; Marsden, John; McCluskey, Connor; Boley, Randy A; Bradley, Katharine A; Campbell, Cynthia I; Curtis, Megan E; Fiellin, David; Ghitza, Udi; Hefner, Kathryn; Hser, Yih-Ing; McHugh, R Kathryn; McPherson, Sterling M; Mooney, Larissa J; Moran, Landhing M; Murphy, Sean M; Schwartz, Robert P; Shmueli-Blumberg, Dikla; Shulman, Matisyahu; Stephens, Kari A; Watkins, Katherine E; Weiss, Roger D; Wu, Li-TzyBackground and aim
There is no gold-standard and considerable heterogeneity in outcome measures used to evaluate treatments for opioid use disorder (OUD) along the opioid treatment cascade. The aim of this study was to develop the US National Institute on Drug Abuse (NIDA) National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder core outcomes set (OUD-COS).Design
Four round, e-Delphi expert panel consensus study and plenary research group discussion and targeted consultation.Setting
USA.Participants
A panel of 25 members including clinical practitioners, clinical researchers, and administrative staff from the CTN, the network's affiliated clinical and community sites, and the NIDA Centre for the CTN.Measurements
From a pool of 24 candidate items in four domains (biomedical/disease status; behaviors, symptoms, and functioning; opioid treatment cascade; and morbidity and mortality), the panel completed an online questionnaire to rank items with defined specification, on a 9-point scale for importance, with a standard 70% consensus criterion.Findings
After the fourth round of the questionnaire and subsequent discussion, consensus was reached for five outcomes: two patient reported (global impression of improvement and incident non-fatal overdose); one clinician reported (illicit/non-medical drug toxicology); and two from administrative records (duration of treatment and fatal opioid poisoning).Conclusions
An e-Delphi consensus study has produced the US National Institute on Drug Abuse (NIDA) National Drug Abuse Treatment Clinical Trials Network opioid use disorder core outcomes set (version 1) for opioid use disorder treatment efficacy and effectiveness research.